Intermittent Docetaxel as First-line for Metastatic CRPCIntermittent Docetaxel as First-line for Metastatic CRPC
Does intermittent administration of docetaxel improve quality of life for patients with castration resistant prostate cancer? Future Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
More News: Cancer | Cancer & Oncology | Docetaxel | Health | Hematology | Prostate Cancer | Taxotere